Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27562376 | 0.77 | RAB9A (0.64) | RAB9ARECQLNPC1MAPTALDH1A1 | |
| SCHEMBL1013991 | 0.76 | RAB9A (0.67) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL6672199 | 0.74 | RAB9A (0.65) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL17324735 | 0.73 | SMN1; SMN2 (0.76) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3878040 | 0.71 | ALDH1A1 (0.42) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL28769766 | 0.71 | RAB9A (0.59) | RAB9ARECQLNPC1MAPTALDH1A1 | |
| SCHEMBL28771220 | 0.70 | KMT2A (0.50) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11710697 | 0.69 | RAB9A (0.57) | RAB9ARECQLNPC1MAPTALDH1A1 | |
| SCHEMBL27712585 | 0.69 | XPO1 (0.47) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL11796988 | 0.69 | ALDH1A1 (0.56) | RAB9AMAPTALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682105-A4 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2008-12-24 | — | — | EP | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| EP-1682105-A2 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005048932-A2 | N-UREIDOALKYL-AMINO COMPOUNDS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153970-A1 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | ACKR3, CCL11, GPR17 | RAB9A 1021/4885RECQL 4200/4885NPC1 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.